

Abstract

5 The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of  
medicaments for the treatment of angiodependent diseases. More specifically, the invention  
relates to the use of the aforesaid compound and, in particular, the calcium and potassium  
salts thereof, for the treatment of two angiodependent diseases, which present a reduction in  
the apoptosis, namely cancer and psoriasis. The invention also discloses the  
antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of  
10 compounds in non-quiescent cells. In addition, the invention details the potentiating effect  
of said compounds on known cytostatic medicines in the treatment of tumours and,  
specifically, on gliomas. The invention further relates to the therapeutic efficacy of said  
compounds, based on the combined antiproliferative, antiangiogenic and proapoptotic  
capacities thereof, in the treatment of chronic psoriatic plaques.